Tinlarebant Explained

Cas Number:	1821327-95-0
Pubchem:	92044505
Drugbank:	DB17832
Chemspiderid:	68006872
Unii:	63WI9S8P1M
Kegg:	D12351
Chembl:	3967849
Iupac Name:	1-[3-[4-[3,4-difluoro-2-(trifluoromethyl)phenyl]piperidine-1-carbonyl]-1,4,5,7-tetrahydropyrazolo[3,4-c]pyridin-6-yl]ethanone
C:	21
H:	21
F:	5
N:	4
O:	2
Smiles:	CC(=O)N1CCC2=C(C1)NN=C2C(=O)N3CCC(CC3)C4=C(C(=C(C=C4)F)F)C(F)(F)F
Stdinchi:	1S/C21H21F5N4O2/c1-11(31)30-9-6-14-16(10-30)27-28-19(14)20(32)29-7-4-12(5-8-29)13-2-3-15(22)18(23)17(13)21(24,25)26/h2-3,12H,4-10H2,1H3,(H,27,28)
Stdinchikey:	HAGSLCBZFRRBLS-UHFFFAOYSA-N

Tinlarebant is a investigational new drug that is being evaluated to treat dry macular degeneration and Stargardt disease.^[1] It is a retinol binding protein 4 antagonist.^[2]

Notes and References

Web site: Tinlarebant - Belite Bio . AdisInsight . Springer Nature Switzerland AG .
Kim N, Priefer R . Retinol binding protein 4 antagonists and protein synthesis inhibitors: Potential for therapeutic development . European Journal of Medicinal Chemistry . 226 . 113856 . December 2021 . 34547506 . 10.1016/j.ejmech.2021.113856 .